(1) Accord Healthcare Ltd & anr (appellants) v The Regents of the University of California & anr (respondents) (2) Sandoz AG & anr (appellants) v The Regents of the University of California & anr (respondents) (3) Teva Pharmaceutical Industries Ltd & anr (appellants) v The Regents of the University of California & anr (respondents)
Wednesday 2 July 2025
All of the appellants appeal the Order dated 7 November 2024 of Mr Justice Mellor sitting as a High Court Judge in the Business and Property Courts, Patents Court in which the Judge held that the Patent and SPC were valid and dismissed the Claimant’s claims.
The underlying dispute is in relation to the validity and infringement of the European Patent and the corresponding SPC.
The Accord, Sandoz and Teva Appellants are independent companies who wanted to launch generic enzalutamide (also referred to as RD162) used for treating prostate cancer in the UK further to having been granted marketing authorisations in the UK.
View hearing: